UNSPSC 51393400: Sympathomimetic or adrenergic xanthines

This classification denotes Sympathomimetic or adrenergic drugs made from purine bases found in body tissues and fluids and in some plants.

UNSPSC 51393400 Sympathomimetic or adrenergic xanthines is a Class code that in recent state and local procurement activity covers the acquisition of pharmaceutical products, particularly naloxone and related drug-intervention systems, purchased by public health and human services agencies. State and local health departments and community health programs are the primary issuing bodies soliciting under this code, supported by health and human services commissions operating at the state level. The work involves procuring finished pharmaceutical products for public health initiatives—specifically opioid-overdose response supplies and drug deactivation systems—with delivery typically to county or state health facilities on a recurring or annual basis. Vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify enrollment, and appropriate insurance coverage; contracts often include performance probationary periods and multi-year terms with renewal options.

Recent activity is concentrated in the South, with Seminole County, Florida issuing IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to explore vendor capacity for direct-to-manufacturer prescription programs within its Therapeutic Pharmacy Initiative, seeking vendor experience with direct contracting for self-insured plans and negotiated net pricing models. The RFI functions as a market-intelligence phase preceding a formal solicitation. These two opportunities suggest that state and local procurement under this code focuses on emergency-response pharmaceuticals and prescription-fulfillment innovation, with health agencies exploring both traditional supply chain models and evolving direct-manufacturer partnerships to improve cost management and operational efficiency.